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OBJECTIVES: This study aimed to characterize and estimate the frequency of adverse reactions to
antituberculosis drugs in the population treated at the Centro de Sau´de Escola Germano Sinval Faria, a
primary health care clinic in Manguinhos, Rio de Janeiro City, and to explore the relationship between adverse
drug reactions and some of the patients’ demographic and health characteristics.
METHODS: This descriptive study was conducted via patient record review of incident cases between 2004 and
2008.
RESULTS: Of the 176 patients studied, 41.5% developed one or more adverse reactions to antituberculosis
drugs, totaling 126 occurrences. The rate of adverse reactions to antituberculosis drugs was higher among
women, patients aged 50 years or older, those with four or more comorbidities, and those who used five or
more drugs. Of the total reactions, 71.4% were mild. The organ systems most affected were as follows: the
gastrointestinal tract (29.4%), the skin and appendages (21.4%), and the central and peripheral nervous
systems (14.3%). Of the patients who experienced adverse reactions to antituberculosis drugs, 65.8% received
no drug treatment for their adverse reactions, and 4.1% had one of the antituberculosis drugs suspended
because of adverse reactions. ‘‘Probable reactions’’ (75%) predominated over ‘‘possible reactions’’ (24%). In the
study sample, 64.3% of the reactions occurred during the first two months of treatment, and most (92.6%) of
the reactions were ascribed to the combination of rifampicin + isoniazid + pyrazinamide (Regimen I). A high
dropout rate from tuberculosis treatment (24.4%) was also observed.
CONCLUSION: This study suggests a high rate of adverse reactions to antituberculosis drugs.
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& INTRODUCTION
Tuberculosis is the chronic infectious disease that kills the
most individuals worldwide. Since 1993, the World Health
Organization (WHO) (1,2) has considered tuberculosis a
global emergency. In 2005, there were an estimated eight
million new cases and approximately two million deaths
per year worldwide, with only half the cases reported to the
WHO (1). The main factors aggravating the situation are
social inequality, the spread of AIDS, an aging population,
major migratory movements (3), improper health care (4),
and a lack of information, which is associated with these
previous factors and one of the key obstacles to controlling
the disease (2).
In Brazil, ‘‘...tuberculosis is neither an emerging nor a re-
emerging public health problem. It is a problem that has
been present and resident for a long time’’ (3). Brazil ranks
19th among countries with the most tuberculosis cases in the
world today (5). Nationwide, some 5,000 to 6,000 deaths
from tuberculosis are recorded annually (6). Recently, the
number of new cases in Brazil has declined significantly,
from 51.44/100,000 in 1999 to 37.12/100,000 in 2008 (7).
Nonetheless, in 2008, incidence in the Rio de Janeiro
municipal area was 68.64/100,000 (8), the highest in the
country, while in some of the municipality’s most under-
served areas, such as the Manguinhos district, annual
incidence reached 145/100,000 (9).
Manguinhos has Rio de Janeiro’s third-lowest Human
Development Index, is considered the city’s worst district in
terms of basic sanitation, and houses a large number of
former prison inmates. Its population profile features a high
proportion of chemical- and alcohol-dependent individuals
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and a large street population that is characterized by
extreme poverty and little schooling. These problems
accentuate the difficulties of controlling tuberculosis (10).
The Ministry of Health (MoH) considers that compliance
with the appropriate recommended therapeutic regimen
makes tuberculosis curable in essentially 100% of cases.
Using antituberculosis drugs correctly for an adequate
period ensures a cure (6).
Although they are effective at combating Mycobacterium
tuberculosis, tuberculosis drugs can cause adverse reactions
that may jeopardize treatment and contribute to nonadher-
ence (11).
An adverse drug reaction (ADR) consists of ‘‘a response
to a drug that is noxious and unintended and occurs at
doses normally used in man for the prophylaxis, diagnosis,
or therapy of disease’’ (12).
Treatment dropout impairs control of the disease, hinders
its cure, and increases treatment time and costs (4).
In Manguinhos and other communities in major urban
centers, the tuberculosis incidence is much higher than the
national and local means; accordingly, this higher incidence
deserves detailed study. This study aimed to characterize
and estimate the frequency of adverse reactions to anti-
tuberculosis drugs in the population treated at the Centro
de Sau´de Escola Germano Sinval Faria (CSEGSF), a primary
health care clinic in Manguinhos, Rio de Janeiro City. In
addition, the study explored the relationship between
adverse drug reactions and some of the patients’ demo-
graphic and health characteristics.
& METHODS
This study forms part of the project ‘‘Fatores associados aos
desfechos do tratamento da tuberculose em um centro de
atenc¸a˜o ba´sica de sau´de: uma ana´lise sob a o´tica antropolo´-
gica e epidemiolo´gica’’ (13) [Factors associated with tubercu-
losis treatment outcomes at a primary health care clinic: an
anthropological and epidemiological analysis], which is
financed by the Global Fund to Fight Tuberculosis, Aids
and Malaria and conducted at CSEGSF/ENSP/Fiocruz/RJ.
Information was drawn from the Rio de Janeiro compul-
sory notifications database (SINAN/SMS RJ), patient
records, the CSEGSF case log book, and the computerized
patient register. These sources served as the basis for project
researchers (13) to define the tuberculosis ‘‘cases’’ used for
the study of adverse reactions.
Study design and population
This study was descriptive via retrospective review of
patient medical records.
The population consisted of new pulmonary tuberculosis
cases treated at the CSEGSF outpatient department.
According to the MoH Manual Te´cnico para o Controle da
Tuberculosis, a case of tuberculosis is any individual with a
diagnosis confirmed by sputum smear test or culture and for
whom the physician establishes a diagnosis of tuberculosis
based on clinical and epidemiological data and the results of
complementary examinations. A new case is someone with
tuberculosis who has never undergone antituberculosis
chemotherapy, has done so for less than 30 days, or was
treated for tuberculosis more than five years ago (14).
Included in this study were children, adults, and older
adults of both sexes who were residing in the Manguinhos
district of Rio de Janeiro, diagnosed with pulmonary
tuberculosis, and considered new cases between January
2004 and December 2008. During the study, 291 cases of
tuberculosis were identified in the SINAN, and 370 cases
were identified in the case log book. After matching the
datasets and excluding duplicate records and cases that
were reported more than once because of relapse or return
after dropout, 279 cases remained for patient record
analysis. After the inclusion criteria were applied, 176 cases
remained eligible for the study. The records of 103 patients
were excluded for the following reasons: not being
considered new cases of pulmonary tuberculosis (relapse
or return after dropout, n = 25); residency in other districts
of Rio de Janeiro (n = 14); other types of tuberculosis (n = 12);
not having completed at least 30 days of treatment (n = 13);
transfer for follow-up to another clinic (n = 13); changes of
diagnosis (n = 20); and incomplete records that made it
impossible to identify the closure status (n = 6; Figure 1).
Patients were followed up until case closure by cure,
dropout, failure/multidrug-resistant tuberculosis (MDR-
TB), or death.
Information sources, data collection, and study
variables
For data collection, a patient record data collection form
and a form-completion instructions manual were developed
in an electronic format using Access (v. 2.0, 2003). The two
instruments were standardized and tested.
The information drawn from the patient records was
complemented with project sources (13).
Data were collected by the lead researcher in June and
July 2010. To ensure quality at this stage, two other authors
(LG and SR) collected data again from 10% of the patient
records. At this stage, no major divergences were found.
Some aspects of data recording that had no impact on the
estimates were standardized.
The following variables were considered:
Adverse drug reaction (ADR): Information drawn from
the progress sheets in patients’ records, with the respective
dates.
Case closure status: Information drawn from data
collected for the project (13). The variable categories and
definitions (6) were as follows:
Dropout: ‘‘Any patient who fails to attend the clinic for
more than 30 consecutive days after the scheduled return
date. In cases of supervised treatment, the 30-day limit is
counted from the last drug administration.’’
Failure/MDR-TB: ‘‘Persistently positive sputum smear
tests at the end of treatment. Also classified as ‘Failure’ are
patients who are strongly positive (++ or +++) at start of
treatment and maintain that status until the fourth month,
as well as all those who start treatment positive, then are
negative, then once again positive for two consecutive
months, as of the fourth month of treatment.’’
Death: ‘‘Classified upon learning of the patient’s death
during treatment, regardless of cause.’’
Cure: ‘‘Cases initially positive for pulmonary TB: dis-
charge by cure will be given when, on completing
treatment, the patient returns two negative sputum smear
tests, one during the follow-up stage and one upon
completion of treatment (cure). Discharge by cure will also
be given when treatment is deemed complete based on
clinical and radiological criteria and complementary exam-
inations.’’
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Associated comorbidities: Information drawn from
patient records. All comorbidities were recorded for sub-
sequent analysis using the Naranjo algorithm (15), a tool for
evaluating the causal relationship between drug use and
adverse reaction. The date of occurrence was that of the first
recording of each comorbidity during the patient’s treat-
ment period. The International Classification of Diseases
(ICD-10) was attached to the electronic form so that the ICD
codes described in the record form could be identified and
the morbidities described in the record form could be
assigned an ICD code. All prior diseases, such as hyperten-
sion, diabetes, AIDS, and alcoholism, recorded by the
medical team were considered. Any symptoms or signs
that might be ADRs were also recorded.
Sex and age: information was drawn from patient records.
Age was recorded as a continuous variable and subse-
quently categorized into the following age groups: 0 to 19
years, 20 to 49 years, and 50 years or older.
Drugs used: Information was drawn from patient record
progress sheets, with prescription dates. Antituberculosis
drugs (rifampicin, isoniazid, pyrazinamide) and other
drugs, both continuous- and occasional-use, were consid-
ered. The following categories were created for the
antituberculosis drugs: prescribed (P), suspended by patient
(SP), suspended by medical practitioner (SM), dropout (D),
completion of therapy (C), and non-protocol doses (P*). For
the analysis of the total number of antituberculosis and
other drugs used, two categories were created: up to four
and five or more. Drugs used during treatment were
counted, and repeat prescriptions were disregarded.
Data analysis
Two components were considered in the analysis: patients
and ADRs. The data on patients and ADRs are given in absolute
values and as proportions. The mean and median behavior of
the continuous variables was also noted. Proportions were
compared using the Pearson chi-squared (x2) test.
Patients were classified by occurrence of ADR with the
aid of the Naranjo algorithm, which contains ten questions,
each of which receives a score. The questions specifically
address the compatibility between when the reaction
appeared and when the drug was taken; the nature of the
reaction; the drug’s pharmacological characteristics; and
alternative causes (15). The algorithm enables ADRs to be
classified as ‘‘definite’’, ‘‘probable’’, ‘‘possible’’, or ‘‘doubt-
ful’’. In the case of doubtful reactions, patients were
classified as not experiencing an ADR.
Recording the dates of interest (prescription of each drug;
appearance of the ADR; comorbidities identified) made it
possible to rigorously identify the time relation between
prior exposure to the drugs and the subsequent appearance
of adverse reactions.
ADRs were classified by the organ system affected
according to WHO terminology (WHO-ART, 2005) (16)
and described by type, period of occurrence, and severity.
Severity classifications were based on the MoH defini-
tions (6), as follows: mild effects, in which there is no
immediate modification of the standard regimen, and major
effects, which may entail interruption or alteration of the
treatment. The identification of ADRs not described by
MoH was based on the scientific literature (17,18,19,20).
Figure 1 - Flowchart of cases of tuberculosis (TB) included in the study, CSEGSF/ENSP/FIOCRUZ-RJ, 2004-2008.
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To explore the relationships between the ADRs and the
characteristics of the study population, a multiple corre-
spondence analysis (MCA) was used. This is a descriptive or
exploratory multivariate technique.
The analysis was essentially graphic and was conducted
by observing proximity among points in a multidimensional
space representing the spatial configuration of the cate-
gories of variables analyzed (21).
The analyses were performed using the statistical package
SPSS for Windows, Version 17.0. Correspondence analysis
was performed using the software XLSTAT 4.0.
Ethical considerations
The project was approved by the Oswaldo Cruz
Foundation (CEP/ENSP/Fiocruz) ethics committee for
research with human subjects under Number
0038.0.031.000-09.
& RESULTS
The 176 patients selected were included in the analyses.
Their ages ranged from 1 to 85 years (mean = 32.4 years;
median = 29 years). Of the participants, 113 (64.2%) were
male, 128 (72.7%) were 20 to 49 years old, 161 (91.5%) had
up to three recorded comorbidities, and 117 (66.5%) used up
to four drugs (Table 1). Of the total patient population, 126
(71.6%) were cured, while 43 (24.4%) dropped out of
treatment, five (2.8%) died from tuberculosis, one (0.6%)
died from other causes, and one (0.6%) had multidrug-
resistant tuberculosis. The mean number of drugs used was
4.46 (median = 3).
The most frequent comorbidities among the patients
studied were lifestyle-related problems (tobacco and/or
alcohol; 23.4%), hypertension (12.6%), diabetes (11.7%), and
HIV (10.8%).
In the study sample, the proportion of ADRs among
women was greater than among men (54.0% vs. 34.5%).
Patients aged 50 years or older displayed a higher
proportion of ADRs than other age groups (52.4% vs.
22.2% among the 0- to 19-year-old subjects). The stratum
with four or more comorbidities showed a higher propor-
tion of ADRs than others (80.0% vs. 20.6% for no
comorbidities). The stratum using five or more drugs
showed a higher proportion of ADRs (61% vs. 31.6% among
users of up to four drugs; Table 1).
Of the 176 patients studied, 73 (41.5%) developed one or
more ADRs, for a total of 126 occurrences (Tables 1 and 2).
Of the 73 patients with ADRs, 39 developed only one ADR,
while 34 patients developed two or more ADRs during the
study period.
Approximately 78% (98/126) of the ADRs are described
in the MoH epidemiological surveillance guide (Guia de
Vigilaˆncia Epidemiolo´gica) (6). Of the ADRs found in this
study, 71.4% were considered mild reactions, 6.4% were
major, and 22.2% were considered ‘‘other’’. Of the latter, the
most frequent (32.1%) was dizziness (Table 2). No death
from antituberculosis ADR was observed.
Of the total patients with ADRs, 48 (65.8%) received no
drug treatment for the ADR, and three (4.1%) had one of the
antituberculosis drugs suspended because of an adverse
reaction.
The organ systems most affected by ADRs were the
gastrointestinal tract (29.4%), the skin and appendages
(21.4%), the central and peripheral nervous systems
(14.3%), and the musculoskeletal system (10.3%).
Disturbances of the urinary system, the liver and gall
bladder, the female reproductive system, the white and red
blood cells and reticuloendothelial system, metabolism and
nutrition, and the overall state of health and psychiatric
disturbances were also found. Each of these disturbance
types comprised between 0.8 and 5.5% of the cases
analyzed.
Table 3 describes the ADRs according to the treatment
period during which they occurred and according to the
severity of the ADR and the related drugs. ADRs may be
associated with more than one drug, which share an array of
undesirable side-effects, attributable in part to common
pharmacokinetic processes. In the study sample, 81 (64.3%)
of the reactions occurred during the first two months of
treatment, and most reactions (92.6%) were imputed to the
combination of rifampicin + isoniazid + pyrazinamide
(Regimen I). The severest ADRs tended to occur from the
third month of treatment onwards (p,0.05).
The likelihood of an adverse reaction being caused by the
drugs was analyzed using the Naranjo algorithm. The
results showed a predominance of probable reactions (75%),
followed by possible reactions (24%) and definite reactions
(1%).
A high rate of dropout from TB treatment (24.4%) was
observed (43/176). The dropout rate was higher among the
men than women (29.4% vs. 18.3%) and higher among
younger people (37% were from 0 to 19 years old vs. 23.6%
in the 20 to 49 years group and 21.1% in the 50 years or older
group), although the differences were not statistically
significant. Dropout was also observed to be greater
(p,0.05) among those with no recorded comorbidities
(38.7% vs. 18.5% with one to three comorbidities and
13.3% with four or more comorbidities), those who used
up to four drugs (32.7% vs. 10.7% of users of five or more
drugs), and those who developed no adverse reactions to
the antituberculosis drugs (34.0% vs. 13.0% among those
with an ADR).
Table 1 - Population characteristics of new tuberculosis
cases by occurrence of adverse reactions (ADRs) to
antituberculosis drugs, CSEGSF/ENSP/FIOCRUZ-RJ, 2004-
2008.
Patient
Characteristics Without ADRs With ADRs Total
N (%) N (%) N (%)
Gender
Male 74 (65.5) 39 (34.5) 113 (64.2)
Female* 29 (46.0) 34 (54.0) 63 (35.8)
Age group
0 to 19 years 21 (77.8) 6 (22.2) 27 (15.3)
20 to 49 years * 72 (56.2) 56 (43.8) 128 (72.7)
50 years or older * 10 (47.6) 11 (52.4) 21 (12.0)
Comorbidities #
None 50 (79.4) 13 (20.6) 63 (35.8)
1 to 3** 50 (51.0) 48 (49.0) 98 (55.7)
4 or more** 3 (20.0) 12 (80.0) 15 (8.5)
Number of drugs
0 to 4 80 (68.4) 37 (31.6) 117 (66.5)
5 or more** 23 (39.0) 36 (61.0) 59 (33.5)
Total 103 (58.5) 73 (41.5) 176 (100.0)
*p,0.05;
**p,0.01.
# By International Statistical Classification of Diseases code number.
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The graph analysis appears to show two groups, each
represented by one ellipse. The small ellipse shows the
group of individuals who dropped out of treatment, are
male, used up to four drugs, had no comorbidities, and did
not develop ADRs (A, M, F1, C1, and N). The bigger ellipse
shows the group of individuals who were cured, were aged
20 to 49 years, used more than five drugs, presented one to
three comorbidities, and developed ADRs (C, I2, F2, C2, and
S; Figure 2).
& DISCUSSION
The cases of tuberculosis treated at the CSEGSF/Ensp/
Fiocruz were predominantly patients who were men,
adults, had up to three comorbidities, used up to four
drugs, and evolved to cure.
One of the main findings of this study was that 42% of the
patients presented antituberculosis ADRs, three-quarters of
which were classified as ‘‘probable’’. Of the total ADRs, 78%
were described in the MoH epidemiological surveillance
guide (Guia de Vigilaˆncia Epidemiolo´gica), and 71% were
considered mild. One-third of the reactions affected the
gastrointestinal system, although essentially all systems
were affected.
The study showed a high rate of ADRs, similar to that
found by a study in Sa˜o Paulo city (22) (49.1%) among
patients treated at a teaching hospital outpatient depart-
ment. In Canada, a retrospective study of 1,061 patients
Table 2 - Frequency of adverse drug reactions (ADRs) to antituberculosis drugs by type and severity, CSEGSF/ENSP/
FIOCRUZ-RJ, 2004-2008.
Description of adverse reactions N (%)
Minor adverse reactions 90 71.4
Gastric irritation (nausea, vomiting), abdominal pain 37 29.3
Itchy skin 20 15.9
Arthralgia or arthritis 13 10.3
Headache 6 4.8
Sweat and urine orange 6 4.8
Behavior change (euphoria, insomnia, anxiety, and drowsiness) 4 3.1
Peripheral neuropathy (burning of the extremities) 3 2.4
Fever 1 0.8
Major adverse reactions 8 6.4
Exanthema 3 2.4
Hepatotoxicity (vomiting, hepatitis, changes in liver function tests) 3 2.4
Thrombocytopenia, leukopenia, eosinophilia, hemolytic anemia, agranulocytosis, vasculitis 2 1.6
Other1 28 22.2
Total 126 100.0
1ADRs not described in the MoH Guia de Vigilaˆncia Epidemiolo´gica: adenopathy, hallucinations, amenorrhea, anemia, increased uric acid, increased
menstrual flow, painful urination, rash, weakness, jaundice, desquamative (scaly) lesions on the knees, urticarial lesions, malaise (sickness), other
psychotic disorders, allergic reactions, and dizziness.
Table 3 - Adverse drug reactions (ADRs) to antituberculosis drugs by severity, drugs involved, and treatment period,
CSEGSF/ENSP/FIOCRUZ-RJ, 2004-2008.
Up to 2nd month N (%) 3rd month onwards N (%) Total ADRs N (%)
Type of ADR # *
Minor 64 (71.1) 26 (28.9) 90 (91.8)
Major 3 (37.5) 5 (62.5) * 8 (8.2)
Drugs
R+H+Z 50 (92.6) 4 (0.8) 54 (42.9)
R+H 16 (42.1) 22 (57.9) 38 (30.2)
R 7 (50.0) 7 (50.0) 14 (11.1)
H 3 (33.3) 6 (66.7) 9 (7.1)
R+Z 2 (100.0) - 2 (1.59)
Z - 1 (100.0) 1 (0.8)
R+E 1 (100.0) - 1 (0.8)
R+H+E - 1 (100.0) 1 (0.8)
R+H+Z+E - 1 (100.0) 1 (0.8)
Other combinations1 2 (40.0) 3 (60.0) 5 (4.0)
Total 81 (64.3) 45 (35.7) 126 (100.0)
*p,0.05.
#Twenty-eight ADRs were excluded because they are not described in the MoH Guia de Vigilaˆncia Epidemiolo´gica. Half of the ADRs occurred during the
first two months of treatment.
R = rifampicin; H = isoniazid; Z = pyrazinamide; E = ethambutol.
1Other combinations include: rifampicin + ethinylestradiol; rifampicin + isoniazid + paracetamol + sulfadiazine + sulfamethoxazole + omeprazole;
rifampicin + efavirenz + metronidazole + sulfamethoxazole; rifampicin + isoniazid + efavirenz + sulfadiazine + sulfamethoxazole + pyrimethamine;
isoniazid with alcohol intake.
D – dropout; C – cure; N – no ADR; S – ADR present; F – female; M – male; I1 – aged 0 to 19 years.; I2 – aged 20 to 49 years; I3 – aged 50 or older years; F1 –
used up to four drugs; F2 – used five or more drugs; C1 – no comorbidity; C2 – one to three comorbidities; C3 – more than three comorbidities.
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found a 30% rate of adverse reactions to antituberculosis
drugs (23). However, prospective studies in Brazil have
shown that the rate adverse reactions to antituberculosis
drugs may be still higher, reaching 83.5% of patients (24).
The positive associations between ADR and female sex
and advanced age may have differing interpretations, as
found in other studies (11,25,26). Regarding female sex, the
mechanism is unknown; however, previous interpretations
include hormonal oscillations at different stages of life that
modify drug responses; interactions between antitubercu-
losis and contraceptive drugs that may favor the appearance
of ADRs (17,19); or greater attendance at health services,
which would facilitate the detection of ADRs. Regarding
age, the older population is more prone to develop ADRs,
particularly the most severe forms (11,23,25,26). Patients
older than 60 years are likely to experience intoxications
from these drugs (14) because both hepatic and renal
metabolisms can be impaired with age, favoring the
accumulation of metabolites and the occurrence of ADRs
(27).
Tuberculosis may be concomitant with other diseases,
thus increasing the number of drugs patients use and
predisposing them toward adverse reactions. In the study
sample, patients who used more than five drugs in the
course of their treatment developed more ADRs. Kishore
et al. (11) observed in India that nearly half the patients who
developed ADRs were prescribed more than five drugs.
In terms of severity, a higher frequency of mild reactions
was observed. This is consistent with the findings of a study
conducted in Sa˜o Paulo city, in which 81% of the ADRs were
considered mild, and the most common ADRs were
abdominal pain (20.4%) and arthralgia (16.4%) (22).
Regarding the nature of the ADRs, gastrointestinal
disturbances, skin conditions, and joint pains were the most
commonly identified problems. Gastrointestinal distur-
bances, which are characterized by gastric irritation, nausea,
vomiting, and abdominal pain, were present in the
epidemiological studies (11,22,23,25) at frequencies ranging
from 14.28% (11) to 29.7% (22). It is particularly important to
note reactions that impair the liver because they may
require interrupting treatment and may even lead to death.
In a national study of 297 patients in Sa˜o Paulo, 3.7% of the
patients (n = 11) had their drug regimen altered because of
adverse reactions, and hepatotoxicity was responsible for
Figure 2 - Graphic display of patient characteristics according to the occurrence of adverse drug reactions (ADRs) to antituberculosis
drugs, the Centro de Sau´de Escola Germano Sinval Faria/ENSP/FIOCRUZ-RJ, from 2004 to 2008 through the two dimensions of
correspondence analysis.
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63.7% of the changes (22). Compared with other studies
(11,22,23,25), our sample showed a low percentage of
hepatotoxicity (2.4%), which may be explained in part by
the fact that complementary examinations to detect
evidence of hepatic alterations could not be performed on
the 43 patients (24.4%) who dropped out of treatment.
Only 30.1% of the antituberculosis ADRs were treated at
CSEGSF. ADRs must be identified and treated to prevent
similar reactions, reduce health service costs, and minimize
patient suffering.
ADRs are known to occur predominantly in the early
months of tuberculosis treatment (22,25,26,28), although
severe effects, such as hepatotoxicity, may occur later, after
the fifth month of treatment (29). Similarly, in our study,
most (64.3%) of the ADRs occurred in the first two months
of treatment, which may be explained by the fact that the
three drugs associated with most of the ADRs were used
simultaneously during that period.
Establishing the probability that the relationship between
drug and ADR is causal (causality) depends largely on the
information obtained, particularly regarding alternative
causes, such as other diseases and the use of other drugs.
Our findings permit most (75%) of the adverse reactions to
be characterized as probably occasioned by the drugs. A
retrospective study of 326 patients in India found an
estimate similar to ours (72.5%) (11). Meanwhile, a retro-
spective study of 1,061 patients in Canada classified 51.7%
as likely and 20.9% as definitely drug-caused (23).
Instruments for analyzing causality (30,31) are grounded
in basic considerations, such as temporality, pharmacologi-
cal plausibility, and alternative causes. For that reason, the
Naranjo probabilities scale (15), a method that has been
previously validated, in widespread use for several decades,
and applied in both prospective and retrospective studies,
was used in this study.
Even given the use of tools to ensure that causality is
judged objectively, the quality of the information obtained
in each study and the source of scientific evidence can
explain the variations between estimates.
The drugs for tuberculosis are effective and should be
used in the correct dosages for a period of six months. One
factor of concern is the rate of treatment dropout before the
end of that period, which impairs the drugs’ effectiveness
and can lead to multiple-drug resistance. For that reason, we
were surprised at the percentage of patients who dropped
out of treatment (24.4%). In 2001, the national mean dropout
rate was approximately 12% (32), and it reached 27.3% in
some state capitals (33). The WHO target is to reduce that
rate to 5% (34). The high dropout rate reflects the
tuberculosis scenario in many localities in Brazil, where
social problems such as hunger, extreme poverty, violence,
and drug abuse are themselves risk factors for treatment
dropout [36]. It is thus possible that for these patients,
adherence to tuberculosis treatment involves other issues
that require more complex, systemic solutions.
Losses from patients who dropped out of treatment
between January 2004 and December 2008 prevented an
analysis of the association between dropout and ADRs. To
explore the hypothesis that the adverse effects of the
treatment may lead to dropout would entail actively finding
the cases that failed to attend the clinic. That would be
extremely difficult in the context of this study, in which the
time lag would make it difficult to trace losses.
Alternatively, approaches could be developed to include
prospective follow-up of the participants, as will be
discussed below.
From the correspondence analysis, it was possible to
identify two groups. The first comprised predominantly
men, younger patients, those with fewer comorbidities and
adverse reactions, those using fewer drugs, and those who
dropped out of treatment. Interestingly, higher dropout
rates among men and among young patients were also
observed in another retrospective study of 481 smear-
positive patients conducted in Cuiaba´ (Mato Grosso) from
1998 to 2000 (25). The second group included predomi-
nantly women, older patients, those with more comorbid-
ities and adverse reactions, those using more drugs, and
those who evolved to cure.
It is plausible that the second group frequented the clinic
more assiduously, which would enable the adverse reac-
tions to be more readily identified and recorded. The group
comprising mainly men, young patients, and those with
fewer comorbidities may have dropped out of treatment;
accordingly, fewer adverse reactions were recorded. This
latter group may have been more irregular in the treatment
(failing to take the drugs for a few days), may have
presented milder adverse reactions more often in the first
two months, and may not have returned to the clinic for
subsequent appointments. Thus, those who dropped out of
treatment would have demographic characteristics that
would warrant supposing that the ADRs may have been
the reason for dropout. There may, however, be other more
important reasons, such as the socioeconomic situation
itself, in the case of young patients.
Regarding the study’s limitations, it should be noted that
the retrospective design, handwritten patient records, and
patients’ failure to attend appointments may all have
undermined the credibility of the information on the drugs
prescribed, dosages and frequency of drug use by the
patients, and the patients’ clinical progression. Nonetheless,
given the overall quality of the records and the complete-
ness of the information observed during data collection, it
can be said that generally, the validity of the records is
assured and did not impair the general information about
exposure to the drugs. Regarding the information on social
variables, such as schooling, little information was entered
in the records: no information on level of schooling was
available for 71.6% (126/176) of the patients studied.
The information in the clinic’s patient records was
sufficient for the study of ADRs, and the estimates are
compatible with expected values. The fact that the clinic in
question engages in technology development, research, and
teaching in the health field certainly contributed to our
ability to obtain information of acceptable quality and
quantity. Electronic patient records and prescriptions and
improvements in patient data recording may be introduced
in the future and would contribute to improving the quality
of research at the clinic.
Furthermore, regarding methodological considerations, it
should be noted that the differences in the study designs
hindered comparisons of their results. It should also be
remembered that in many countries, the main tuberculosis
treatment regimen includes ethambutol (which was only
recently adopted in Brazil) and streptomycin, which are
considered first-line drugs.
For analysis purposes, the information on comorbidities
was considered only once, at the date of the first entry in the
patient record. Additionally, the comorbidities and ADRs
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were assumed to be concomitant, regardless of the date
when the comorbidities were recorded. That is because the
retrospective design and degree of irregularity in attending
appointments made it impossible to guarantee whether
acute conditions recorded at a time inconsistent with
(previous or subsequent to) the occurrence of the ADR
actually occurred at the time of the ADR. For chronic
conditions, such as hypertension or diabetes, that assump-
tion does not entail errors. For acute, symptomatic condi-
tions, however, comorbidities may have been over-
estimated, and ADRs may have been underestimated.
A literature search found no studies addressing the
association between dropout and the incidence of adverse
reactions, in part because observational studies of adverse
reactions to tuberculosis treatment are still scarce in Brazil.
Future studies should examine that association, although
the difficulties of such an examination are not insignificant.
In retrospective studies, such as the present one, testing
associations is problematical because the occurrence of ADRs
among patients who dropped out of treatment is recorded
only for the period during which the patient remains in
treatment, and that time varies from individual to individual.
In prospective studies, testing the association between
adverse reactions and dropout would raise ethical issues
and entail modifying the definition of the outcome variable.
Here, dropout from treatment was considered to be failure to
attend an appointment for 30 days or more, which was based
on the MoH criteria. A prospective approach could consider
the intention to drop out of treatment or the failure to attend
an appointment for a shorter period. In addition, detecting
patients who dropped out of treatment could also yield
useful information about the reasons for dropout, which may
include the occurrence of ADRs.
To conclude, this study suggests a high rate of ADRs,
which were detected particularly in one subgroup of patients.
Various measures can be taken to reduce those figures,
particularly measures to increase awareness among patients
and health personnel. Regarding the latter, it would be
necessary to introduce changes to the work process and how
production is organized, with a view toward spreading
technical knowledge about the occurrence of ADRs and
establishing mechanisms so that ADRs are appropriately
recorded, treated and controlled. From a research standpoint,
prospective studies in the population of the Manguinhos
district and others with similar social and economic profiles
could produce new information to help control adverse
reactions and increase adherence to tuberculosis treatment.
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